BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Genencor International, Inc. (GCOR) Launches Revolutionary Enzyme Technology For Prion Decontamination


3/27/2006 10:40:15 AM

PALO ALTO, Calif., March 27 /PRNewswire/ -- Genencor International, Inc. announced today a European Notified Body has assessed and certified the first enzyme technology designed specifically as a prion disinfectant for medical devices. Prions, the causative agents of Bovine Spongiform Encephalopathy (BSE) and its human form, variant Creutzfeldt-Jakob Disease (vCJD), have been a concern in countries like the United Kingdom in recent years due to a lack of technology to reduce the risk from the protein-based particles on medical instruments. Developed jointly with the United Kingdom's Health Protection Agency (HPA) and independently certified for use by a European Community Notified Body, Prionzyme(TM) carries the CE mark (Conformite Europeenne). The product can be used to disinfect medical instruments utilized in invasive surgeries, such as procedures related to the central nervous system, eyes and tonsils, where prions have been shown to accumulate in the body. Genencor plans to further develop its Prionzyme line of products targeted for disinfecting general instruments and for sanitizing equipment for the meat processing industry.

Enzymes are proteins that help a chemical reaction take place specifically, quickly and efficiently and offer a number of advantages over traditional harsh and caustic chemical disinfectant methods such as reducing worker safety issues and are environmentally friendly and simple to use. With the launch of Prionzyme, hospitals and sterilization units now have access to a new, highly efficient technology to help them reduce the risk of prion contamination.

"Using the tools of biotechnology to address important issues facing the world today, Genencor is very pleased to commercialize the first enzyme technology to target this unconventional, infectious agent," said Thomas Pekich, president of Genencor. "Our partnership with the HPA combined with the protease technology expertise we've built over the past two decades has been key to addressing this difficult problem."

The use of Genencor's Prionzyme for medical instruments combines the proprietary enzyme with temperature and pH conditions. The product is added as the first step in a presoak process with stainless steel instruments. "This technology will be easily adaptable to current procedures and equipment already in place in hospitals and clinics," said John Gell, vice president, Industrial Specialties for Genencor. "Prionzyme also offers a number of benefits including minimizing worker safety issues by reducing exposure to harsh chemicals; lessening the environmental impact as enzymes biodegrade in disinfectant solution versus concern about disposal of caustic chemicals and providing material compatibility where proteases have been used in conjunction with stainless steel and other components for decades. We are now identifying marketing partners to bring the technology to the medical industry quickly and effectively."

Prionzyme M, the first enzyme from the new line of products, carries the CE mark indicating that the protease conforms with the essential requirements established by the European Medical Device Directive 93/42/EEC. Genencor plans for its additional Prionzyme products to also carry the CE designation. Genencor also recently received the ISO 13485:2003 registration at its Cedar Rapids, Iowa production site, where the Prionzyme products are manufactured. Following an extensive audit of the site's quality systems, Lloyd's Register Quality Assurance, a leading International Standards Organization (ISO) registrar and European Community Notified Body, awarded the ISO 13485 certificate of registration.

For more information about Prionzyme enzymes, contact Genencor at +1-800-847-5311 (USA only) or +1-800-256-5200.

About Genencor

Genencor International, a division of Danisco A/S, is a leading industrial biotechnology company that develops innovative enzymes and bioproducts to improve the performance and reduce the environmental impact of the cleaning, textiles, fuels and chemicals industries.

Genencor International

CONTACT: Angie Blackwell, +1-585-256-6973



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES